Home > Insider Trading > Filing (0001144204-13-063844)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1270073	Intercept Pharmaceuticals Inc	ICPT	Pharmaceutical Preparations (2834)	223868459

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1559512	Luciano Adorini	C/O Intercept Pharmaceuticals, Inc. 18 Desbrosses Street New York NY 10013	Chief Scientific Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2013-11-20	2,000	$10.40	7,743	No	4	M	Direct
Common Stock	Disposition	2013-11-20	1,620	$50.50	6,123	No	4	S	Direct
Common Stock	Disposition	2013-11-20	380	$51.26	5,743	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Options to Purchase Common Stock	Disposition	2013-11-20	2,000	$0.00	2,000	$10.40

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
9,634		2018-01-07	No	4	M	Direct

Footnotes

The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on May 16, 2013.
All shares underlying this option have fully vested.
This transaction was executed in multiple trades at prices ranging from $49.96 to $50.90. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
This transaction was executed in multiple trades at prices ranging from $51.00 to $51.34. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.